Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

AMS, Memphasys, Osram, ProSiebenSat.1 Media - valuable access to customers

Access to customers is of high importance for most companies. Building brands is also a matter of trust. Before a company or product is established as a brand, an average of seven contacts or encounters must have taken place. The situation is different with recommendations fro...
Mario Hose | May 15, 2020 |

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. Clinical-stage biopharmaceutical company Protago...
Streetwise Reports | December 5, 2019 |

Imagin Medical Poised for Breakout with Bladder Cancer Detection Device in FDA Approval Process

A new advancement in bladder-related endoscopic surgery is endorsed and de-risked. You don't often hear about it, but bladder cancer is the sixth most common cancer in the U.S., with approximately 80,000 cases reported every year, and some 600,000 Americans living in ...
Streetwise Reports | November 13, 2019 |

Buzz on the Bullboards: New Coronavirus Opportunities

Every obstacle can be an opportunity, and the COVID-19 crisis has put the investment spotlight on companies stepping up to the plate. What we once talked about as a looming and uncertain threat has quickly become the new norm. The coronavirus pandemic has upended lives, b...
Omri Wallach | April 1, 2020 |

Disruptive Technology Poised to Deliver Significant Advancement in Bladder Cancer Detection

Chris Temple, editor and publisher of The National Investor, explains why he recommends this small-cap as a Buy. Imagin Medical's disruptive technology is poised to deliver the most significant advancement in bladder cancer detection and removal in decades , ma...
Streetwise Reports | January 15, 2020 |

Software For Safe Medical Cannabis Access

Alternate Health’s integrated health services features clinical laboratories and CanaPass - online patient management software for safe access to medical cannabis. Currently generating revenue, Alternate Health plans to reinvest profit...
BTV-Business Television | June 9, 2018 |

Virus Curve, Market Crash, and Mortgage Massacre

In this last segment of our multi-part research article, we want to highlight our expectations of the Covid-19 virus event and how the next 6+ months of global market activity may play out. We’ve covered some of the data points we believe are important and we...
Chris Vermeulen | March 25, 2020 |

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data

Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. Neurodegen...
Streetwise Reports | December 9, 2019 |

MediciNova Shares Rise 40% on Plans to Initiate COVID-19 ARDS Clinical Trial

Shares of MediciNova traded higher after the company reported that it plans to initiate a clinical study of MN-166 (ibudilast) for COVID-19 acute respiratory distress syndrome. Biopharmaceutical company MediciNova, Inc. yesterday announced that "it will ...
Streetwise Reports | April 13, 2020 |

Buzz on the Bullboards: Defending Voter Rights

(Image via @porkchopchili.) There is one burning topic among Stockhouse’s Bullboards of late … the showdown for the White House. Early voting is underway in the US for what is a presidential election for the ages and as we all know, there has been ...
Stockhouse Editorial | October 21, 2020 |
1 2 3 4 5 6 7 8 9 10 ...